



abbvie

#47

Tarik Rahmanovic

Director, Research & Active Measures and Emerging Technologies

AbbVie

Public role source revisited. Employer/self sources and association/event biographies are distinguished; direct role acceptance is not established. **Current-role source**

Direct business email and telephone: not publicly verified.

Public professional route: named role biography. Personal LinkedIn URL remains unverified.

Source: health-isac.org

Work base: Not established from reviewed sources. Actual work base, DC access and willingness require direct confirmation.

Recommendation and rationale

Hold for title/remit qualification. Technical research leader and sector director; enterprise sponsorship and desired board role unresolved.

Research rank #47 - Sponsor / remit qualification. Final research recommendation for this pass; ISA selection and outreach approval pending.

Company capacity and proposed benefit

FY2025 total net revenues approximately \$61.2bn. **Source: www.abbvie.com**

Proposed company benefit: Validate current AbbVie relevance of the older presentation and identify an enterprise sponsor.

Proposed executive benefit: Contribute technical risk and automation experience.

What This Recruit Could Add to ISA

Translate vulnerability automation into accountable ownership, validation and escalation measures. **Source: www.qualys.com**

Handbook connection: Tool K 66-68. Proposed output and benefits require agreement. **Source: www.nacdonline.org**

Introduction and next decision

No named introducer established. ISA to designate an approved contact route; no private relationship inferred.

ISA to reconcile account status and route; then validate current remit, contribution, corporate payer and participation directly.

Policy history and board-selection fit

Policy evidence gap: Reviewed commentary supports an operating or governance perspective, but attributable testimony, formal policy input or a government advisory role has not been verified in this pass.

Current public roster; reviewed October 12, 2026 - Board of Directors. Health-ISAC lists AbbVie research and cyber-threat leadership. [Source: health-isac.org](https://health-isac.org)

Director/scientist remit is not enterprise CISO authority. Sector service does not establish budget approval.

Benchmark: ISA recommendations, current ISA board practitioner profile, operating authority, company capacity, attributable policy work, concrete contribution, and portfolio balance. Corporate directorship alone does not determine priority.

Qualification status and ownership

Requirement	Evidence and remaining confirmation
Current role	Public role support; recheck directly before contact; direct confirmation pending.
ISA membership	Unknown current company/account and designated-representative status. Public board absence does not establish nonmembership.
Eligibility	Conditional representative fit. ISA acceptance and employer designation pending.
Board feedback / introducer	No named introducer established. Introduction completion: not confirmed.
Corporate sponsorship	Published annual dues \$75,000; corporate payer, budget approver and written authorization not confirmed.
Executive interest	Not directly confirmed. Published interest in cyber topics is not membership interest.
Time / participation	Four meetings yearly, including two in Washington, DC and two virtual, plus agreed preparation. Availability, travel and term commitment not confirmed.
ISA output and benefits	Person-specific hypotheses documented; prospect and employer acceptance not confirmed.
Portfolio	Industry/expertise rationale assessed. Work base and DC access require direct confirmation.

[ISA public board / meeting baseline](#) | [Bylaws](#) | [Published sponsorship](#)

1631 owns researched case and source accuracy; ISA owns current membership/eligibility/introducer decision; employer/prospect must confirm funding, interest, availability and proposed output.

Image and contact provenance

Portrait: Name-matched image on named public biography. [Source: health-isac.org](https://health-isac.org)

Company mark: Exact named source asset; manually selected [Source: health-isac.org](https://health-isac.org)

Attributable commentary and evidence ledger

1 / 10 substantive sightings recorded. Depth target remains open; no biographies, awards or duplicate syndications added to fill the gap.

1. Implementing a Fully Automatic Vulnerability Management Program by Tarik Rahmanovic

2012 | Published presentation outline [Source: www.qualys.com](http://www.qualys.com)

Organizes vulnerability-management automation around ownership, validation, reporting and escalation problems.

Attribution / limitation: Historical OfficeMax role; slide outline reviewed, not recording.

ISA relevance: Operational accountability and assurance.